The research progress of high altitude environment-associated chronic obstructive pulmonary disease and therapeutic drugs.
- Author:
Xiang-Hai ZENG
1
;
Ge-Le SUONAN
2
;
Qin HUANG
1
;
Yu LI
1
;
Xiao-Jing ZHANG
1
;
Wen-Bin LI
1
;
Rong WANG
1
Author Information
1. Department of Pharmacy, the 940th Hospital of the Joint Logistic Support Force, Lanzhou 730050, China.
2. Department of Internal Medicine, Qinghai Yushu People's Hospital, Yushu 815099, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Altitude;
Pulmonary Disease, Chronic Obstructive/drug therapy*;
Oxygen;
Hypoxia
- From:
Acta Physiologica Sinica
2023;75(5):691-702
- CountryChina
- Language:Chinese
-
Abstract:
The plateau environment is characterized by low oxygen, low air pressure, low temperature, and strong ultraviolet rays, etc. Chronic obstructive pulmonary disease (COPD) is a preventable and treatable chronic lung disease. High altitude environment increases COPD prevalence, clinical manifestation and mortality. The therapeutic window of theophylline drugs for COPD is narrow, and the high altitude environment has an influence on the pharmacokinetics of the drugs. This review summarizes the differences in the prevalence, mortality, clinical manifestation and clinical symptoms of COPD in the plateau and plain, providing a basis for identifying the risk factors of COPD in the plateau areas. The effects of plateau hypoxic environment on the pharmacokinetics of COPD drugs were also discussed. It can provide a rationale for more effective prevention and treatment of COPD at high altitude.
